The expression of the von Hippel-Lindau gene product and its impact on invasiveness of human breast cancer cells

International Journal of Molecular Medicine

Volumn 20, Issue 4, 2007, Pages 605-611

  Zia, Mohammad K ^a   Rmali, Khaled A ^a   Gareth, Watkins ^a   Mansel, Robert E ^a   Jiang, Wen G ^a  

^a CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

Breast cancer; Tumour progression; Tumour suppressor gene; Von Hippel Lindau

Indexed keywords

MESSENGER RNA; RNA; VON HIPPEL LINDAU PROTEIN;

ARTICLE; BREAST TUMOR; CANCER INVASION; CELL MOTION; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; METASTASIS; PATHOLOGY; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL; TREATMENT OUTCOME; TUMOR CELL LINE;

BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 38449111737     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.20.4.605     Document Type: Article

References (37)

1. Kaelin WG, Iliopoulos O, Lonergan KM, et al: Functions of the von Hippel-Lindau tumour suppressor protein. J Int Med 43: 535-539, 1998.
2. Neumann HP, Lips CJ, Hsia YE and Zbar B: Von Hippel-Lindau syndrome. Brain Pathol 5: 181-193, 1995.
3. Richard S, David P, Marsot-Dupuch K, et al: Central nervous system hemangioblastomas, endolymphatic sac tumours, and von Hippel-Lindau disease. Neurosurg Rev 23: 1-22, 2000.
4. Couch V, Lindor NM, Karnes PS, et al: Von Hippel-Lindau disease. Mayo Clin Proc 75: 265-272, 2000.
5. Lantzsch T, Hefler L, Koelbl H, et al: Expression of the von Hippel-Lindau gene protein in breast cancer tissue. Gynecol Oncol 84: 186-187, 2002.
6. Gilcrease MZ, Schmidt L and Zabar B: Somatic von Hippel-Lindau mutation in clear cell papillary cystadenoma of the epididymis. Hum Pathol 26: 1342-1346, 1995.
7. Hoang MP, Hruban RH and Albores-Saavedra J: Clear cell endocrine pancreatic tumour mimicking renal cell carcinoma: a distinctive neoplasm of von Hippel-Lindau disease. Am J Surg Pathol 25: 602-609, 2001.
8. Lubensky IA, Pack S, Ault D, et al: Multiple neuroendocrine tumours of the pancreas in von Hippel-Lindau disease patients: histopathological and molecular genetic analysis. Am J Pathol 153: 223-231, 1998.
9. Cybulski C, Krzystolik K, Murgia A, et al: Germline mutations in the von Hippel-Lindau (VHL) gene in patients from Poland: disease presentation in patients with deletions of the entire VHL gene. J Med Genet 39: E38, 2002.
10. Joerger M, Koeberle D, Neumann HP, et al: Von Hippel-Lindau disease - a rare disease important to recognize. Onkologie 28: 159-163, 2005.
11. Sano T and Horiguchi H: Von Hippel-Lindau disease. Microsc Res Tech 60: 159-164, 2003.
12. Seizinger BR, Rouleau GA, Ozelius LJ, et al: von Hippel-Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma. Nature 332: 268-269, 1988.
13. Latif F, Tory K, Gnarra J, et al: Identification of the von Hippel-Lindau disease tumour suppressor gene. Science 260: 1317-1320, 1993. (Pubitemid 23231974)
14. Kim WY and Kaelin WG: Role of VHL gene mutation in human cancer. J Clin Oncol 22: 4991-5004, 2004.
15. Martinez A, Walker RA, Shaw JA, et al: Chromosome 3p allele loss in early invasive breast cancer: detailed mapping and association with clinicopathological features. Mol Pathol 54: 300-306, 2001.
16. Sourvinos G, Miyakis S, Liloglou TL, et al: Von Hippel-Lindau tumour suppressor gene is not involved in sporadic human breast cancer. Tumour Biol 22: 131-136, 2001.
17. Esteller M: Epigenetic lesions causing genetic lesions in human cancer: promoter hypermethylation of DNA repair genes. Eur J Cancer 36: 2294-2300, 2000.
18. Chim CS, Liang R and Kwong YL: Hypermethylation of gene promoters in haematological neoplasia. Hematol Oncol 20: 167-176, 2002.
19. Jiang WG, Watkins G, Lane J, et al: Prognostic value of Rho GTPases and Rho guanine nucleotide dissociation inhibitors in human breast cancers. Clin Cancer Res 9: 6432-6440, 2003.
20. Blancher C, Moore JW, Robertson N, et al: Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3-kinase/Akt signalling pathway. Cancer Res 61: 7349-7355, 2001.
21. Gnarra JR, Zhou S, Merrill MJ, et al: Post-transcriptional regulation of vascular endothelial growth factor mRNA, by the product of the VHL tumour suppressor gene. Proc Natl Acad Sci USA 93: 10589-10594, 1996.
22. Wizigmann-Voos S, Breier G, Risau W, et al: Up-regulation of vascular endothelial growth factor and its receptors in von Hippel-Lindau disease associated and sporadic hemangioblastomas. Cancer Res 55: 1358-1364, 1995.
23. Jiang WG, Davies G, Martin TA, Parr C, Watkins G, Mason MD, Mokbel K and Mansel RE: Molecular targeting of matrilysin and its impact on tumour growth in vivo, the potential implications in breast cancer therapy. Clin Cancer Res 11: 6012-6019, 2005.
24. Ye L, Lewis-Rusell J, Kynaston H and Jiang WG: Regulation of BMP receptor expression in human prostate cancer cells by hepatocyte growth factor. Int J Oncol 30: 521-529, 2007.
25. Jiang WG, Davies G, Martin TA, Mason MD, Kynaston H and Fodstad O: Com-1/p8 is a putative tumour suppressor in prostate cancer. Int J Mol Med 18: 981-986, 2006.
26. Jiang WG, Davies G, Martin TA, Parr C, Watkins G, Mason MD and Mansel RE: Expression of membrane type-1 matrix metalloproteinase, MT1-MMP, in human breast cancer and its impact on invasiveness of breast cancer cells. Int J Mol Med 17: 583-590, 2006.
27. Jiang WG, Hiscox S, SK Singhrao, Puntis MCA, Nakamura T and Hallett MB: Inhibition of HGF/SF induced membrane ruffling and cell motility by transient elevation of cytosolic free calcium. Exp Cell Res 200: 424-433, 1995.
28. Corless CL, Kibel AS, Iliopoulos O, et al: Immunostaining of the von Hippel-Lindau gene product in normal and neoplastic human tissues. Hum Pathol 28: 459-464, 1996.
29. Zbar B, Kaelin W, Chen F, et al: Third international meeting on von Hippel-Lindau disease. Cancer Res 59: 2251-2253, 1999.
30. Kibel A, Iliopoulos O, DeCaprio JA Jr and Kaelin WG: Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C. Science 269: 1444-1446, 1995.
31. Duan DR, Pause A, Burgess WH, et al: Inhibition of transcription elongation by the VHL tumor suppressor protein. Science 269: 1402-1406, 1995.
32. Feldman DE, Thulasiraman V, Ferreyra RG, et al: Formation of the VHL-elongin BC tumor suppressor complex is mediated by the chaperonin TRiC. Mol Cell Biochem 4: 1051-1061, 1999.
33. Lee S, Neumann M, Stearman R, et al: Transcription-dependent nuclear-cytoplasmic trafficking is required for the function of the von Hippel-Lindau tumor suppressor protein. Mol Cell Biol 19: 1486-1497, 1999.
34. Ohh M and Kaelin WG Jr: The von Hippel-Lindau tumour suppressor protein: new perspectives. Mol Med Today 5: 257-263, 1999.
35. Stebbins CE, Kaelin WG Jr and Pavletich NP: Structure of the VHL-ElonginC-ElonginB complex: implications for VHL tumor suppressor function. Science 284: 455-461, 1999.
36. Schoenfeld AR, Davidowitz EJ and Burk RD: Elongin BC complex prevents degradation of von Hippel-Lindau tumor suppressor gene products. Proc Natl Acad Sci USA 97: 8507-8512, 2000.
37. Pause A, Lee S, Worrell RA, et al: The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins. Proc Natl Acad Sci USA 94: 2156-2161, 1997.